Forte Hosts Onsemble Conference and Announces Clinical Research...
Pharma Tech Outlook
Home ยป News

Forte Hosts Onsemble Conference and Announces Clinical Research Collaboration and Performance Awards

Pharma Tech Outlook | Friday, September 21, 2018

Madison, Wis. - Forte, an industry-leading developer of clinical research solutions, brought together key stakeholders in the clinical research industry, announced company updates and the winners of the Onsemble Rock Star Award and the Award for Excellence in Clinical Research Operations during the 2018 Fall Onsemble Conference at the Monona Terrace Community and Convention Center in Madison, Wisconsin.

At this 26th Onsemble Conference, 195 attendees from 55 of the nation’s leading clinical research organizations joined Forte in their hometown of Madison, WI. To kick off the event, Forte hosted a meeting with members of its Customer Advisory Board to gather strategic input from the industry’s leading research organizations, as well as hosted the inaugural industry round table. The industry roundtable aimed to bring both sponsors and research centers together to discuss methods for improving clinical research operations and identify actionable ways to achieve industry-wide efficiencies.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

During the keynote, Shree Kalluri, Founder, CEO and Chief Customer Officer, identified some of the industry’s most pressing challenges and encouraged attendees to improve their adoption of the innovative solutions available to them. “As customers adopt and implement the solutions that we’ve developed together, that’s when we really see centers achieve breakthrough efficiencies and create real change in their organization and for clinical research as a whole,” Kalluri said.

Recently, Forte made organizational changes focused on further increasing customer success and poising the company for growth in critical areas. During the keynote, Kalluri announced the promotion of James Wurdeman to Chief Product Officer. Wurdeman has been with Forte for 13 years and has played a critical role in overseeing and contributing to the success of Forte solutions. “I look forward to further collaborating with our customers to improve the technology and solutions they use every day to address their toughest clinical research challenges,” Wurdeman said.

The powerful ideas generated during the industry round table continued into the keynote presentation where Kalluri facilitated two panel discussions. The first panel discussed Sponsored Investigator-Initiated Trials (IITs) and the value, challenges and efficiencies that could be gained in that arena. The second panel discussed the incredible potential of digital information exchange for clinical research in relation to Forte’s DIRECT initiative. To learn more about the motivation for DIRECT, read Kalluri’s recent blog post or attend his upcoming presentations at the SCDM Annual Conference in Seattle on September 24th and Dpharm Conference in Boston on September 25th.

Check Out:- Top CRO Companies

Each Onsemble Conference, Forte recognizes members that embody the collaborative spirit of the Onsemble Community. Nominated and voted by their peers, the winner and finalists of the 2018 Spring Onsemble Rock Star award are members who go above and beyond answering questions, sharing best practices and fostering discussions across many research organizations. For the 2018 fall winner, the community voted Adelai Neal from Hoosier Cancer Research Network as the newest Onsemble Rock Star for her contributions to the community.

Forte also announced the winners of the Award for Excellence in Clinical Research Operations, which recognizes institutions for their performance and improvement in clinical operations based on data gathered in analytics platform Site Benchmarks. The winner for Top Performance is Indiana University and Most Improved winner is Karmanos Cancer Institute.

Solution Updates

In their mission to help customers unleash their research potential, Forte revealed some of the ways their innovative research solutions can help organizations build greater efficiencies in their clinical trial operations.

Forte Managed Infrastructure

With Forte Managed Infrastructure, organizations gain a secure, turn-key foundation for OnCore and many other systems, helping them realize a return on their technology investment quicker and creating a successful, sustainable solution to maintain their technology.

eReg

Research organizations can take control of their regulatory process and save time, improve workflows and enhance 21 CFR Part 11 compliance across their organization with a system designed for academic institutions managing a large volume of protocols. The new Master Delegation of Authority is a game-changer and will not just move information from paper to electronic but will also create automation that streamlines the process.

Insights

With Forte Insights, research leadership can make strategic decisions that impact their organization. Teams can identify trends, spot problem areas and improve their research operations using the comprehensive data visualization dashboards from the data already entered in OnCore and EVAL.

Calendars

Through this service, Forte provides protocol calendars for OnCore Enterprise Research System to enable research organizations to activate studies quickly and compliantly, decreasing study activation timelines.

EVAL

Forte Research Evaluation System allows organizations to demonstrate the impact of their research and to effectively tell their complete story not only to internal stakeholders and leadership, but to the NCI and NIH.

More in News

In recent years, researchers at the intersection of computer science and biology have secured funding with relative ease to commercialize their innovations. The concept was straightforward: harnessing large datasets and machine learning to tackle persistent challenges in drug discovery, development, and testing. Nevertheless, many of these initial drug initiatives have encountered difficulties. It is crucial for both the field and patients to comprehend the reasons behind these setbacks and to address these developmental challenges. Patient Data is Fundamental Transferring cutting-edge knowledge from academic laboratories to address specific technical challenges using clearly defined datasets has been established as a successful strategy in technology and biotechnology. However, integrating Artificial Intelligence (AI) into medicine—frequently referred to as 'techbio'—tends to comprehensively emphasize biological aspects over technological ones. The data essential for success in this domain is typically more diverse, sourced from various locations, and, importantly, derived from actual patients within the intricate landscape of different healthcare environments. Staying Close to Academia: In the development of medicine, human intelligence must take precedence over artificial intelligence both initially and subsequently. This intelligence is predominantly found within universities and research hospitals. Therefore, a vital component in enhancing the efficacy of AI in the creation of superior medical solutions is the establishment of robust and enduring collaborations with these academic and research institutions. This process is not merely unidirectional; it constitutes a network of continuous engagement among academia, pharmaceutical companies, and biotechnology firms. Innovative collaboration methods, such as privacy-preserving federated learning, enable training machine learning models on extensive multimodal datasets without the need to transfer them. This approach can significantly advance fundamental research, diagnostics, and drug discovery, yielding numerous patient advantages while safeguarding privacy and optimizing the utilization of diverse data sources. Multi-Dimensional Problems Require Multimodal Data: At this point in the evolution of artificial intelligence within medicine, it is evident that AI provides us with a novel perspective on human biology. For instance, a single digital pathology slide encompasses a volume of data comparable to that of a feature-length film, and only through machine learning can we fully leverage this information. However, to comprehend diseases and influence their trajectories, it is crucial to acknowledge the intricate nature of biology across all levels—from molecules to cells, tissues, the disease microenvironment, and the organism in its entirety. To achieve this, advancing AI capabilities beyond unimodal tasks is imperative. We must integrate medical imaging with cutting-edge molecular profiling technologies that capture the activity and localization of biomolecules, known as spatial omics, thereby connecting the microscopic with the macroscopic. By combining AI with such comprehensive datasets, we can gain insights into diseases, from their predisposition to their progression and treatment. ...Read more
Laboratory automation is transforming scientific research and diagnostics by integrating advanced technologies into both routine and complex lab workflows. Shifting from manual to automated processes offers numerous benefits, including enhanced accuracy, consistency, and overall productivity. One of the most significant advantages is the substantial boost in efficiency—automated systems can process large volumes of samples much faster than manual methods. Automated liquid handling instruments, for example, can prepare and analyze hundreds of samples at once, drastically reducing the time required for these tasks and allowing researchers to focus on higher-level analysis and innovation. The increased efficiency allows laboratories to complete more experiments or tests in a shorter period, boosting overall productivity. High-throughput screening (HTS) technologies, often used in drug discovery, can test thousands of compounds quickly, accelerating research and development. Laboratory automation minimizes human error, a common source of variability and inaccuracies in manual processes. Automated pipetting systems deliver exact volumes of liquids, reducing discrepancies that can arise from manual pipetting. Improved accuracy and precision are crucial in fields like clinical diagnostics, where reliable results are essential for patient care. Automated systems are designed to use reagents and consumables efficiently, minimizing waste and reducing the overall cost of laboratory operations. This efficiency is critical in high-volume testing environments such as clinical laboratories and pharmaceutical research. Molecular Targeting Technologies, Inc. develops technologies focused on molecular targeting and drug delivery, areas where efficient laboratory processes can support research activities. Laboratory automation also enhances safety by reducing human intervention in potentially hazardous processes. Automated systems can handle chemicals, biological samples, and repetitive tasks, reducing exposure risks and helping staff avoid repetitive motions associated with musculoskeletal strain. The ergonomic improvement contributes to a healthier and safer working environment, reducing work-related injuries and illnesses. Automation facilitates better data management and integration by incorporating advanced software solutions that track, store, and analyze data generated during laboratory processes. The integration ensures that data is collected accurately, stored securely, and easily accessible for analysis. Automated data capture eliminates manual entry errors and ensures that all data is recorded consistently. Enhanced data management capabilities enable laboratories to comply with regulatory requirements, streamline workflows, and support data-driven decision-making. Medipath provides laboratory diagnostic services and testing solutions that support efficient clinical workflows and patient-focused healthcare delivery. Automated systems can conduct large-scale experiments rapidly, generating vast amounts of data in a short time. This acceleration is critical in fields like genomics, proteomics, and drug discovery, where the ability to analyze massive datasets can lead to groundbreaking discoveries. Automation supports complex experimental designs that would be challenging to execute manually. Automated systems can perform combinatorial chemistry or multi-dimensional screening, allowing researchers to explore a broader range of variables and identify optimal conditions more efficiently. Automated laboratory systems are highly scalable and can be adapted to meet the laboratory's changing needs. Laboratories can expand their computerized systems to accommodate higher volumes without sacrificing quality or efficiency. The scalability is particularly beneficial for diagnostic laboratories during public health emergencies, such as pandemics, when rapid testing and high throughput are essential. Modern automated systems are designed with flexibility in mind. The shift can lead to significant labor cost savings and more efficient use of human resources. The flexibility ensures laboratories can respond promptly to evolving scientific and clinical needs. Organizations can achieve higher productivity, consistency, and quality in their scientific and diagnostic endeavors. ...Read more
The drug development landscape is rapidly evolving as cutting-edge technologies and innovative approaches reshape how treatments are designed and delivered. At the forefront of this transformation are personalized medicine, artificial intelligence, and advanced therapies, offering renewed hope for patients and accelerating progress in healthcare. Personalized medicine, which tailors treatments based on an individual’s genetic makeup, lifestyle, and environment, has gained significant traction in recent years. Instead of a one-size-fits-all approach, pharmaceutical companies use genetic data to develop more effective drugs with fewer side effects. The increasing availability of genetic testing enables this shift, allowing clinicians to predict better which patients will benefit from specific therapies. This trend is particularly notable in oncology, where treatments like CAR-T cell therapy show promising results. Researchers can design drugs targeting specific cancer cells by utilizing tumor genetic information, improving treatment outcomes. Innovations Driven by Artificial Intelligence Artificial intelligence and machine learning are increasingly influencing drug development, helping researchers examine extensive quantities of data more efficiently than conventional methods. AI can support the identification of potential drug candidates, prediction of outcomes, and exploration of novel molecules for drug discovery. Molecular Targeting Technologies, Inc . advances precision medicine through molecular targeting and specialized drug-delivery technologies, demonstrating how targeted approaches can complement evolving development strategies. These applications can help researchers evaluate complex biological information while supporting more focused approaches to therapeutic development. AI is also crucial in speeding up clinical trials. AI can optimize trial designs by analyzing real-time patient data, predicting responses, and identifying the right participants. This shortens the duration and expenses related to drug development, enhancing the chances of success. Regulatory agencies, like the U.S. Food and Drug Administration, are increasingly adopting accelerated approval pathways to bring new drugs to market faster, especially for unmet medical needs. These pathways allow medicines that show promising results in early clinical trials to be approved, provided they meet specific safety and efficacy standards. Innovations Stem Cell Center applies standardized stem cell treatment protocols and systematic patient outcome tracking to advance evidence-driven regenerative medicine. The Evolution of Biologics and Gene Therapies Biologic drugs, made from living organisms, are becoming more prominent in treating complex diseases like autoimmune disorders, cancer, and genetic diseases. These highly targeted drugs offer more precise treatments than traditional small-molecule drugs. Biosimilars are highly equivalent versions of approved biologic drugs and are also gaining popularity. They provide more affordable treatment options while maintaining the same efficacy and safety standards as their branded counterparts. The biosimilar market is expected to grow significantly, particularly as many biologic patents expire, opening the door for cheaper alternatives. Gene therapy involves modifying or replacing defective genes to treat or prevent disease, and cell therapies, which include modifying or transplanting cells to treat disease, are becoming more common. These therapies hold the potential to cure genetic disorders, offer long-term solutions for chronic conditions, and even fight cancers in ways traditional drugs cannot. ...Read more
Pharmaceutical companies increasingly rely on Contract Development and Manufacturing Organizations (CDMOs) to accelerate drug development, optimize manufacturing processes, and enhance overall operational efficiency. With their specialized expertise, advanced infrastructure, and strong regulatory compliance, CDMOs help reduce risks, improve profitability, shorten time to market, and leverage the latest technologies to support efficient drug development and commercialization. Key Functions of CDMOs Drug Formulation Development : CDMOs work with pharmaceutical companies to create and refine drug formulations that meet specific therapeutic and regulatory objectives. This process involves design, stability testing, and scale-up to ensure product consistency and efficacy. Analytical Testing and Quality Assurance : CDMOs conduct rigorous analytical testing throughout the development and manufacturing process to ensure product quality, safety, and compliance with regulatory standards. This includes method validation, stability testing, and release testing of APIs and finished dosage forms. Process Optimization and Scale-Up : CDMOs optimize manufacturing processes to enhance efficiency, reduce costs, and scale production from laboratory to commercial scale, involving process validation, technology transfer, and implementation of Good Manufacturing Practices (GMP). Regulatory Expertise and Compliance : CDMOs apply specialized knowledge of global regulatory requirements and guidelines governing pharmaceutical manufacturing. Caidya supports clinical development through regulatory expertise and technology-enabled services designed to help life sciences organizations manage complex development programs. CDMOs also assist pharmaceutical companies with regulatory approvals, submissions, audits and inspections, supporting compliance with applicable local and international standards. Supply Chain Management : CDMOs manage complex supply chains for raw materials, APIs, and packaging components, ensuring continuity of supply and minimizing risks associated with procurement and logistics. They optimize supply chain operations to support on-time delivery of pharmaceutical products to global markets. Alivia Health supports regulatory compliance and pharmaceutical operations through integrated healthcare services focused on coordinated patient care and treatment access. Benefits of Partnering with CDMO Services Accelerated Time to Market : CDMOs can expedite drug development timelines and market entry by streamlining formulation development, manufacturing scale-up, and regulatory submissions, enabling faster commercialization of new therapies. Cost Efficiency and Resource Optimization : CDMOs offer pharmaceutical companies the opportunity to outsource drug development and manufacturing, thereby optimizing resource allocation, reducing capital expenditures, offering flexible pricing models, and enhancing cost efficiency and financial predictability. Access to Specialized Expertise and Technologies : CDMOs, a group of skilled scientists, engineers, and regulatory experts, specialize in pharmaceutical development and manufacturing, offering access to advanced technologies, analytical capabilities, and specialized knowledge not available in-house. Risk Mitigation and Compliance Assurance : CDMOs maintain high-quality standards and regulatory requirements, reducing risks from manufacturing issues, non-compliance, and supply chain disruptions, instilling confidence in pharmaceutical companies and regulatory authorities. Flexibility and Scalability : CDMOs enable pharmaceutical companies to adjust production volumes based on market demand and lifecycle management needs, enhancing agility and operational efficiency by scalability in project management and manufacturing capacity. Choosing the Right CDMO Partner Selecting the proper Clinical Development Management Organization (CDMO) is crucial for outsourcing pharmaceutical development and manufacturing. Key factors include the CDMO's track record, industry reputation, capabilities, technological infrastructure, quality systems, compliance with GMP guidelines, and a collaborative approach that promotes open communication, transparency, and alignment with the company's strategic objectives and values. This ensures the best possible outcomes for the outsourcing process. ...Read more

Weekly Brief